Moody's Affirms Ratings of Mylan (MYL) Amid Meda Acquisition Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mylan (MYL) Ratings Affirmed by Fitch Amid Meda Deal; Outlook Remains Stable
February 11, 2016 3:04 PM ESTFitch Ratings has affirmed the long-term Issuer Default Rating (IDR) of Mylan N.V. (Nasdaq: MYL), and the long-term ratings of its subsidiary Mylan, Inc., at 'BBB-' following the announcement that Mylan will acquire Meda A.B. (Meda) for approximately $9.9 billion. The Rating Outlook is Stable.
Mylan's ratings apply to approximately $7.3 billion of debt outstanding at Dec. 31, 2015. A full list of rating actions follows at the end of this release.
Fitch views the deal as strategically sound, strengthening Mylan's position in Western Europe while adding new important growth markets, including... More
Mylan (MYL) Shares Look to Stabilize After Pounding on 'Desparate' Meda Deal
February 11, 2016 11:09 AM ESTMylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall. Analysts called the deal,... More
Mylan to buy Swedish drugmaker Meda in $7.2 billion deal
February 10, 2016 4:49 PM ESTBy Natalie Grover
(Reuters) - Generic drugmaker Mylan NV (NASDAQ: MYL) said it would acquire Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company.
The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo (NYSE: PRGO).
Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer. That works out to be nearly twice Meda's last traded price, which had some analysts... More
